{
    "clinical_study": {
        "@rank": "143085", 
        "arm_group": [
            {
                "arm_group_label": "Open-label Extension", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Safety Monitoring", 
                "arm_group_type": "No Intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "This two-part, open-label extension (OLE) and safety monitoring (SM) study will examine the\n      efficacy and safety of continued etrolizumab treatment in moderate to severe ulcerative\n      colitis (UC) patients previously enrolled in etrolizumab Phase III studies."
        }, 
        "brief_title": "Open-label Extension and Safety Study for Patients With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase III Studies", 
        "completion_date": {
            "#text": "August 2025", 
            "@type": "Anticipated"
        }, 
        "condition": "Ulcerative Colitis", 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Ulcer"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Part 1 (Open-label Extension)\n\n          -  Patients previously enrolled in Phase III controlled studies who meet the eligibility\n             criteria for open-label etrolizumab for those studies as described in the protocol\n\n        Part 2 (Safety Monitoring)\n\n          -  Patients who participated in one of the etrolizumab Phase III studies and are not\n             eligible or chose not to enter Part 1 (OLE)\n\n          -  Patients who transfer from Part 1 (OLE)\n\n          -  Completion of the 12-week safety follow-up prior to entering.\n\n        Exclusion Criteria:\n\n        Part 1 (Open-label Extension)\n\n          -  Any new, significant, uncontrolled condition\n\n        Part 2 (Safety Monitoring)\n\n          -  No exclusion criteria"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02118584", 
            "org_study_id": "GA28951"
        }, 
        "intervention": {
            "arm_group_label": "Open-label Extension", 
            "description": "105 mg administered subcutaneously every 4 weeks for up to 7 years or until either commercial availability or the Sponsor's decision to terminate the study.", 
            "intervention_name": "etrolizumab", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "number_of_arms": "2", 
        "official_title": "AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE III STUDIES", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: GA28951 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2025", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Long-term efficacy as determined by partial Mayo Clinic Score (pMCS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 years"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02118584"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}